CER-001
CER-001 is a recombinant high-density lipoprotein (HDL) mimetic that has orphan drug status.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
CER-001 is a recombinant high-density lipoprotein (HDL) mimetic that has orphan drug status. It is in early-stage clinical trials for the potential treatment of hypoalphalipoproteinaemia, acute coronary syndrome (ACS), acute kidney injury (AKI), atherosclerosis and lecithin cholesterol acyltransferase (LCAT) deficiency.
CER-001 is also under investigation as possible agent for treating hyperinflammatory states based on lipid profile alterations due to COVID-19.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1314200846 under CC BY-SA 4.0; modifications have been made.